{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:40:43Z","timestamp":1790127643203,"version":"4.0.1"},"reference-count":54,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T00:00:00Z","timestamp":1664064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Hepatitis E virus (HEV) is the most prevalent hepatitis virus worldwide. Genotypes 3 (HEV3) and 4 (HEV4) as well as rat HEV can lead to chronic hepatitis E and cirrhosis in immunosuppressed patients. Within the last decade, several options for treating chronic hepatitis have been developed and have achieved a sustained virological response. However, there are still unmet needs such as optimizing immunosuppression to allow HEV clearance with or without ribavirin, as well as alternative therapies to ribavirin that are discussed in this paper.<\/jats:p>","DOI":"10.3390\/v14102116","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T04:09:36Z","timestamp":1664424576000},"page":"2116","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Unmet Needs for the Treatment of Chronic Hepatitis E Virus Infection in Immunocompromised Patients"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1930-8964","authenticated-orcid":false,"given":"Nassim","family":"Kamar","sequence":"first","affiliation":[{"name":"Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, 31400 Toulouse, France"},{"name":"INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Disease (Infinity), 31024 Toulouse, France"},{"name":"University Paul Sabatier, 31062 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3115-868X","authenticated-orcid":false,"given":"Arnaud","family":"Del Bello","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, 31400 Toulouse, France"},{"name":"INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Disease (Infinity), 31024 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1753-1065","authenticated-orcid":false,"given":"Florence","family":"Abravanel","sequence":"additional","affiliation":[{"name":"INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Disease (Infinity), 31024 Toulouse, France"},{"name":"University Paul Sabatier, 31062 Toulouse, France"},{"name":"Laboratory of Virology, CHU Purpan, 31300 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuwei","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, 3015 GD Rotterdam, The Netherlands"},{"name":"Erasmus MC Transplant Institute, Erasmus MC-University Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8462-3234","authenticated-orcid":false,"given":"Jacques","family":"Izopet","sequence":"additional","affiliation":[{"name":"INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Disease (Infinity), 31024 Toulouse, France"},{"name":"University Paul Sabatier, 31062 Toulouse, France"},{"name":"Laboratory of Virology, CHU Purpan, 31300 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/S0140-6736(11)61849-7","article-title":"Hepatitis E","volume":"379","author":"Kamar","year":"2012","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17086","DOI":"10.1038\/nrdp.2017.86","article-title":"Hepatitis E virus infection","volume":"3","author":"Kamar","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/cid\/ciab919","article-title":"Hepatitis E virus species C infection in humans, Hong Kong","volume":"75","author":"Sridhar","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jhep.2022.01.028","article-title":"Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: First report in Europe","volume":"77","author":"Frias","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3201\/eid2302.161094","article-title":"Hepatitis E Virus Infection in Solid Organ Transplant Recipients, France","volume":"23","author":"Lhomme","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jhep.2011.06.021","article-title":"Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient","volume":"56","author":"Schlosser","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e12624","DOI":"10.1111\/tid.12624","article-title":"Evidence of hepatitis E virus transmission by renal graft","volume":"19","author":"Pourbaix","year":"2017","journal-title":"Transpl. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S1473-3099(08)70255-X","article-title":"Hepatitis E: An emerging infection in developed countries","volume":"8","author":"Dalton","year":"2008","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa0706992","article-title":"Hepatitis E virus and chronic hepatitis in organ-transplant recipients","volume":"358","author":"Kamar","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1128\/CMR.00057-13","article-title":"Hepatitis E virus infection","volume":"27","author":"Kamar","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/TP.0b013e3181c4096c","article-title":"Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation","volume":"89","author":"Kamar","year":"2010","journal-title":"Transplantation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1053\/j.gastro.2011.02.050","article-title":"Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants","volume":"140","author":"Kamar","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/ajt.12253","article-title":"How should hepatitis E virus infection be defined in organ-transplant recipients?","volume":"13","author":"Kamar","year":"2013","journal-title":"Am. J. Transpl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jcv.2013.10.003","article-title":"Performance of anti-HEV assays for diagnosis acute hepatitis E in immunocompromised patients","volume":"58","author":"Abravanel","year":"2013","journal-title":"J. Clin. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/TP.0000000000001908","article-title":"Summary of the British Transplantation Society UK Guidelines for Hepatitis E and Solid Organ Transplantation","volume":"102","author":"McPherson","year":"2018","journal-title":"Transplantation"},{"key":"ref_16","unstructured":"European Association for the Study of the Liver (2018). Electronic address, e.e.e.; European Association for the Study of the, L. EASL Clinical Practice Guidelines on hepatitis E virus infection. J. Hepatol., 68, 1256\u20131271."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMoa1215246","article-title":"Ribavirin for chronic hepatitis E virus infection in transplant recipients","volume":"370","author":"Kamar","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/cid\/ciz953","article-title":"Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study","volume":"71","author":"Kamar","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.3201\/eid2108.150199","article-title":"Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies","volume":"21","author":"Tavitian","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/cid\/ciu742","article-title":"Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse","volume":"60","author":"Abravanel","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jhep.2018.09.011","article-title":"Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients","volume":"70","author":"Marion","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/AAC.01795-13","article-title":"Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon","volume":"58","author":"Debing","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1053\/j.gastro.2014.02.036","article-title":"Calcineurin Inhibitors Stimulate and Mycophenolic Acid Inhibits Replication of Hepatitis E Virus","volume":"146","author":"Wang","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1097\/TP.0000000000000850","article-title":"An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients","volume":"99","author":"Kamar","year":"2015","journal-title":"Transplantation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/jvh.13432","article-title":"Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection","volume":"28","author":"Mulder","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1136\/gutjnl-2015-311000","article-title":"In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome","volume":"65","author":"Todt","year":"2016","journal-title":"Gut"},{"key":"ref_27","first-page":"474","article-title":"Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b","volume":"16","author":"Haagsma","year":"2010","journal-title":"Liver Transpl."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1086\/650488","article-title":"Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation","volume":"50","author":"Kamar","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/ndt\/gfq282","article-title":"Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient","volume":"25","author":"Kamar","year":"2010","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1097\/00007890-199505270-00012","article-title":"Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients","volume":"59","author":"Rostaing","year":"1995","journal-title":"Transplantation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1432-2277.2008.00831.x","article-title":"Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: An open pilot study","volume":"22","author":"Pageaux","year":"2009","journal-title":"Transpl. Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.gastro.2015.09.011","article-title":"Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin","volume":"150","author":"Debing","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jhep.2020.05.020","article-title":"Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E\u2014The HepNet SofE pilot study","volume":"73","author":"Cornberg","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e00754-17","DOI":"10.1128\/JVI.00754-17","article-title":"Zinc Salts Block Hepatitis E Virus Replication by Inhibiting the Activity of Viral RNA-Dependent RNA Polymerase","volume":"91","author":"Kaushik","year":"2017","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e13050","DOI":"10.1111\/tid.13050","article-title":"Failure to respond to ribavirin despite elevated intra-erythrocyte zinc level in transplant-patients with chronic hepatitis E virus infection","volume":"21","author":"Marion","year":"2019","journal-title":"Transpl. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"105228","DOI":"10.1016\/j.antiviral.2021.105228","article-title":"Niclosamide inhibits hepatitis E virus through suppression of NF-kappaB signalling","volume":"197","author":"Li","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"104997","DOI":"10.1016\/j.antiviral.2020.104997","article-title":"Isocotoin suppresses hepatitis E virus replication through inhibition of heat shock protein 90","volume":"185","author":"Nimgaonkar","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1097\/TP.0000000000001766","article-title":"Chronic Hepatitis E Viral Infection After Liver Transplantation: A Regression of Fibrosis After Antiviral Therapy","volume":"101","author":"Mazzola","year":"2017","journal-title":"Transplantation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/liv.13037","article-title":"Extrahepatic manifestations of hepatitis E virus","volume":"36","author":"Kamar","year":"2016","journal-title":"Liver Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrneurol.2015.234","article-title":"Hepatitis E virus and neurological injury","volume":"12","author":"Dalton","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1212\/WNL.0000000000000111","article-title":"Guillain-Barre syndrome associated with preceding hepatitis E virus infection","volume":"82","author":"Pas","year":"2014","journal-title":"Neurology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1212\/WNL.0000000000000112","article-title":"Neuralgic amyotrophy and hepatitis E virus infection","volume":"82","author":"Madden","year":"2014","journal-title":"Neurology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1212\/WNL.0000000000004297","article-title":"Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy","volume":"89","author":"Dalton","year":"2017","journal-title":"Neurology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3201\/eid1702.100856","article-title":"Hepatitis E virus and neurologic disorders","volume":"17","author":"Kamar","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/j.1600-6143.2010.03068.x","article-title":"Hepatitis E virus-induced neurological symptoms in a kidney-transplant patient with chronic hepatitis","volume":"10","author":"Kamar","year":"2010","journal-title":"Am. J. Transpl."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/TP.0b013e318245f14c","article-title":"Hepatitis E virus and the kidney in solid-organ-transplant patients","volume":"93","author":"Kamar","year":"2012","journal-title":"Transplantation"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"E211","DOI":"10.1111\/tid.12143","article-title":"Hepatitis E virus infection as a new probable cause of de novo membranous nephropathy after kidney transplantation","volume":"15","author":"Taton","year":"2013","journal-title":"Transpl. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/tid.12353","article-title":"Successful treatment of hepatitis E virus-associated cryoglobulinemic membranoproliferative glomerulonephritis with ribavirin","volume":"17","author":"Josse","year":"2015","journal-title":"Transpl. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1128\/JCM.02295-07","article-title":"Severe thrombocytopenia associated with acute hepatitis E virus infection","volume":"46","author":"Colson","year":"2008","journal-title":"J. Clin. Microbiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jcv.2010.02.016","article-title":"Severe thrombocytopenia associated with acute autochthonous hepatitis E","volume":"48","author":"Fourquet","year":"2010","journal-title":"J. Clin. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jcv.2012.02.002","article-title":"Hepatitis E virus-associated aplastic anaemia: The first case of its kind","volume":"54","author":"Shah","year":"2012","journal-title":"J. Clin. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jcv.2011.04.009","article-title":"Acute pancreatitis: A rare complication of acute hepatitis E","volume":"51","author":"Deniel","year":"2011","journal-title":"J. Clin. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s10067-007-0595-0","article-title":"Acute polyarthritis revealing hepatitis E","volume":"26","author":"Serratrice","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jhep.2012.05.010","article-title":"Hepatitis E virus-induced severe myositis","volume":"57","author":"Lavayssiere","year":"2012","journal-title":"J. Hepatol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/10\/2116\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:39:01Z","timestamp":1760143141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/10\/2116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,25]]},"references-count":54,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["v14102116"],"URL":"https:\/\/doi.org\/10.3390\/v14102116","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,25]]}}}